NCT07285759

Investigation of Antibacterial Effect of Levobupivacaine on Staphylococcus Aureus

Experimental Investigation of the Antibacterial Effect of Levobupivacaine on Staphylococcus Aureus in a Patient-Controlled Analgesia (PCA) Model

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Dokuz Eylul University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This experimental in vitro study aimed to investigate the antibacterial effect of levobupivacaine on Staphylococcus aureus in a patient-controlled analgesia (PCA) model at concentrations commonly used for postoperative pain treatment (0.125%) and painless labour (0.0625%). The antibacterial activity was evaluated using colony count reduction and supported by Scanning Electron Microscope (SEM) imaging.

Detailed description

Study solutions were prepared as 100 mL each. Four groups were designed: * Group 1: 0.125% levobupivacaine + 4 mL fentanyl (200 mcg) * Group 2: 0.0625% levobupivacaine + 4 mL fentanyl (200 mcg) * Group 3: 4 mL fentanyl (200 mcg) * Group 4: 99 mL saline (control) Each group received 1 mL of Staphylococcus aureus 0.5 McF (1.5×10⁸ cfu/mL). All samples were infused through a Portex bacterial filter at 4 mL/h for 24 hours using PCA devices. Samples collected from bottles, filter inlets, and outlets were cultivated on Blood Agar. Colony counts were compared statistically using the Kruskal-Wallis and Mann-Whitney U tests (p\<0.05).

Conditions

• Staphylococcus Aureus Bacterial Contamination

Interventions

Type	Name	Description
DRUG	Levobupivacaine	Levobupivacaine is a local anesthetic used at concentrations of 0.125% and 0.0625% to evaluate its antibacterial effect against Staphylococcus aureus in an in vitro PCA model.
DRUG	Fentanyl	Fentanyl is an opioid analgesic used at a concentration of 200 mcg/4 mL, either alone or in combination with levobupivacaine, to assess potential contribution to antibacterial activity.
OTHER	Saline	Sterile saline solution (99 mL) used as the control group to compare antibacterial activity in the PCA infusion model.

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2025-12-16
• Last updated: 2025-12-16